RecruitingNCT07089303

Alzheimer's Disease Multinuclear Imaging Neuro-Enhanced Resolution (AD-MINER)

Ultra-high Field Multimodal and Multinuclear Neuroimaging Cohort Study of Alzheimer's Disease

Sponsor

Chinese PLA General Hospital

Enrollment

750 participants

Start Date

Jul 1, 2025

Study Type

OBSERVATIONAL

Conditions

Alzheimer Disease Mild Cognitive Impairment Due to Alzheimer's Disease

Summary

This single-center prospective cohort study will enroll 750 participants (250 cognitively Normal (CN) individuals, 250 with mild cognitive impairment (MCI), and 250 with Alzheimer's disease (AD)). At baseline and at annual follow-ups, participants will undergo 3 Tesla (3 T) and 7 Tesla (7 T) multimodal magnetic resonance imaging (MRI) scans, blood biomarker testing, genotyping, and cognitive assessments to identify early imaging biomarkers and construct models of disease progression.

Eligibility

Min Age: 55 YearsMax Age: 90 Years

Plain Language Summary

Simplified for easier understanding

This study (AD-MINER) uses advanced brain imaging techniques — including multiple MRI methods — to better understand Alzheimer's disease and related memory disorders. It will follow participants over time to track brain changes and collect biological samples (like blood) to find new disease markers. **You may be eligible if...** - You are 55–90 years old - You are willing to attend baseline and follow-up visits over time - You can undergo MRI scanning (no metal implants or claustrophobia) - You are willing to provide biological samples (e.g., blood) **You may NOT be eligible if...** - You have a contraindication to MRI (metal implants, pacemaker, severe claustrophobia) - You are unable to provide informed consent - You have a condition that would prevent you from completing follow-up visits Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.